RxDoctor Payments Data

Laura Macy, DO

Family Medicine · Auburn, INNPI 1598381295

Payments from drug & device makers

$1,242in general payments, 2019–2025

Across 63 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$244
  • GSK$135
  • Axsome Therapeutics, Inc.$99
  • AstraZeneca$87
  • Lilly USA, LLC$85
  • Novo Nordisk$82
  • plus $509 from 13 others

What the payments were for

  • Food & beverage$1,242100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,242 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$23,259
Medicare patients
81
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$21,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$18,250
RexultiBrexpiprazole15$17,264
TrulicityDulaglutide12$11,802
Albuterol Sulfate HfaAlbuterol Sulfate17$477
Duloxetine Hcl21$425
Levothyroxine Sodium50$392
Bupropion XlBupropion Hcl20$384
Gabapentin22$331
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav40$309
Atorvastatin Calcium41$238
Pregabalin14$224
Mirtazapine11$218
Rosuvastatin Calcium11$215
ClopidogrelClopidogrel Bisulfate18$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$21,59124 claims
GSKTrelegy Ellipta$135$18,25015 claims
Otsuka America Pharmaceutical, Inc.Rexulti$16$17,26415 claims
Lilly USA, LLCTrulicity$85$11,80212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Auburn

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →